Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 85.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 0 · 0%High 0 · 0%

Intranasal steroid drops vs placebo

Presence of normal olfactory function · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

Intranasal steroid drops showed no clear difference in presence of normal olfactory function Assessed by participants > 4… compared with placebo (low certainty).

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
RR 1 [0.89, 1.11]
1 study · 248 participants
Low

Intranasal steroid drops vs placebo

Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Change in taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intranasal steroid drops vs placebo

Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found